key: cord-0279270-4rel013i authors: Saker, K.; Escuret, V.; Pitiot, V.; Massardier-Pilonchery, A.; Paul, S.; Mokdad, B.; Langlois-Jacques, C.; Rabilloud, M.; Goncalves, D.; Fabien, N.; Guibert, N.; Fassier, J.-B.; Bal, A.; Trouillet-Assant, S.; Trabaud, M.-A. title: Evaluation of commercial anti-SARS-CoV-2 antibody assays and comparison of standardized titers in vaccinated healthcare workers. date: 2021-08-26 journal: nan DOI: 10.1101/2021.08.24.21262475 sha: d9d705ecc230bd81fea6d45849b19c2f7727e484 doc_id: 279270 cord_uid: 4rel013i With the availability of vaccines, commercial assays detecting anti-SARS-CoV-2 antibodies (Ab) evolved towards quantitative assays directed to the spike glycoprotein or its receptor binding domain (RBD). The main objective of the present study was to compare the Ab titers obtained with quantitative commercial binding Ab assays, after 1 dose (convalescent individuals) or 2 doses (naive individuals) of vaccine, in healthcare workers (HCW). Antibody titers were measured in 263 sera (from 150 HCW) with 5 quantitative immunoassays (Abbott RBD IgG II quant, bioMerieux RBD IgG, DiaSorin Trimeric spike IgG, Siemens Healthineers RBD IgG, Wantai RBD IgG). One qualitative total antibody anti RBD detection assay (Wantai) was used to detect previous infection before vaccination. The results are presented in binding Ab units (BAU)/mL after application, when possible, of a conversion factor provided by the manufacturers and established from a World Health Organization (WHO) internal standard. There was a 100% seroconversion with all assays evaluated after two doses of vaccine. With assays allowing BAU/ml correction, Ab titers were correlated ({rho}= 0.84-0.99). However, a significant difference between values persisted. The titer differences varied by a mean 3.04% between Siemens and bioMerieux assays to 50.54% between Siemens and DiaSorin assays. Titer harmonization is still to be improved despite better results were obtained between assays detecting the same Ab against the same antigen. The next step towards a true standardization of the assays would be to include the International Standard in the calibration of each assays to express the results in IU/mL. Since the end of 2020, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 50 vaccines have been developed and are now available worldwide with the aim of achieving 51 herd immunity to control the pandemic. Vaccine immunity involves both cellular and humoral 52 pathways. Cellular immunity is not easy to assess on a large scale, as is the neutralizing 53 humoral response owing to requirement for a biosafety level 3 (BSL3) containment 54 laboratory; the evaluation of vaccine effectiveness therefore mainly relies on high throughput 55 serological tests to assess individual humoral immunity as well as monitoring SARS-CoV-2 56 seroprevalence (1). 57 To consider binding antibodies (Ab) as a marker of vaccine effectiveness, several conditions 58 must be met. First, binding Ab assays should be quantitative; second, titers should be 59 consistent between different assays; third, binding Ab titers should correlate with neutralizing 60 Ab titers; fourth, the minimum binding Ab titer associated with virus neutralization must be 61 found; and fifth, the association between neutralizing Ab and vaccine protection must be 62 demonstrated. It can be considered that the first and fifth conditions have been met given that 63 commercial tests for the quantitative detection of binding Ab have been developed (2) (3) (4) (5) (6) (7) , and 64 that the role of neutralizing Ab in the infection protection have been demonstrated in animals 65 and humans (8-11); this is not the case for the other conditions. In particular, the second point 66 is of importance for widespread evaluation of vaccines, but until now Ab titers were often 67 expressed as an index or unit with regard to an internal standard that differs between 68 manufacturers. Recently, the World Health Organization (WHO) has developed an 69 could be tested with the Siemens and DiaSorin IgG assays. 126 Results were expressed by the median and interquartile range [IQR] . Paired comparison 128 between assays was performed using the Wilcoxon test. The correlation between 129 concentrations obtained by each assay was investigated using Pearson correlation coefficients 130 and 95% confidence interval (CI). The Bland-Altman method was used to measure the mean 131 difference and 95% limit of agreement between log-transformed concentrations obtained with 132 each assay Statistical analyses were conducted using GraphPad Prism® software (version 8; 133 GraphPad software, La Jolla, CA, USA). A p-value <0.05 was considered statistically 134 significant. 135 In the first part of the study, the performances of the 6 assays were compared to verify 138 whether the ability to detect anti-SARS-CoV-2 antibodies of the Wantai total Ab assay, which 139 is known to be the most sensitive post infection (13), was similar after vaccination, and 140 whether the sensitivity of qualitative and quantitative assays were also similar. The sera 141 collected from patients scheduled to receive only Pfizer BioNtech vaccine (n=94) were used 142 for this evaluation. Four weeks after the first injection, the proportion of positive samples was 143 over 90% for all assays except the Wantai assay detecting total antibodies (86.1%). Four 144 weeks after the second injection anti SARS CoV-2 antibodies were detected for all 145 participants with all the assays (Table 1) . All assays were negative on pre-pandemic samples 146 from patients with autoantibodies or mycoplasma infection (100% specificity). 147 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org /10.1101 /10. /2021 only the assays adapted or developed for the quantification of Ab induced by vaccine were 149 tested. The Siemens, DiaSorin and bioMérieux assays were compared using sera samples 150 collected before the second injection of vaccine and those collected after full vaccination, and 151 for which assays gave a positive quantitative result (263 samples (Figure 2A , B, C). 160 According to the Bland-Altman method ( Figure 3) and each other assay (p<0.0001; Figure 1B ), but the data from these assays were strongly 170 correlated; the Pearson correlation coefficient (ρ [95%CI]) was 0.99 [0.98; 0.99] between 171 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org /10.1101 /10. /2021 Discussion 176 In the present cohort of vaccinated HCW, the performance of first generation serological 177 assays, developed for diagnosis purpose, as well as second generation ones, adapted or 178 developed in order to assess the vaccine humoral response, were similar. However, first 179 generation assays are not useful to monitor vaccination effectiveness since they are not 180 quantitative or could not be compared to others. The more important finding of the present 181 study was that the quantitative assays, whose results could be standardized to BAU/ml, 182 produce results that are correlated to each other. The Ab titers obtained with the DiaSorin 183 assay, although correlated with those of the others assays, remained higher after conversion 184 using the WHO standard. This may be related to difference in the antigens targeted, as the 185 DiaSorin assay is the only one evaluated in this study, to use the trimeric spike protein (2) . 186 The WHO standard was obtained from the plasma of convalescent patients (12) and must 187 therefore contain antibodies against numerous epitopes, thus the DiaSorin assay is probably 188 capable of reacting with more antibodies than assays detecting only antibodies specific for 189 RBD. 190 There are currently very few reports that have examined Ab binding assays with the use of the 191 WHO standard (3, 7). Perkman et al. (7) CoV-2 RBD IgG from Abbott, used in the present study. In vaccinated individuals, after the 194 first dose of vaccine, titers varied significantly between the assays, but they indicated that the 195 recalculation in BAU/ml with the conversion factor given by the manufacturer did not solve 196 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org /10.1101 /10. /2021 error problems between tests. However, the assays compared were more different in their monomeric spike IgG or anti-trimeric spike IgG. Interestingly, comparison of Abbott and 199 DiaSorin assays found, as was the case herein, higher titers for the DiaSorin assay. Later, 200 Bradley et al. (3) performed linear regressions from sample dilutions of the WHO standard to 201 determine a detection limit in international units (IU) per ml for each test; the authors 202 confirmed the linearity of the Abbott anti-SARS-CoV-2 IgG II Quant assay over the 203 analytical measurement interval but the conversion factor found seemed to be higher than 204 indicated by the manufacturer (1 IU/ml gave 6,1 arbitrary units/ml while Abbott indicated that 205 1 IU correspond to 7.1 arbitrary units). Taken together, these data suggest that there are 206 remaining differences between assays after conversion in BAU/ml and that this could be due 207 to the incorrect adjustment of the correction factor by the manufacturers. The next step for a 208 true harmonization would therefore be to use the international standard to calibrate each assay 209 instead of applying a conversion factor to a result obtained with an assay previously calibrated 210 with an internal standard (14). 211 A limitation of this study is that the specificity analysis was limited to a small group of 212 patients with auto-immune diseases or mycoplasma infection. However, assay specificity 213 analyses have been performed by manufacturers and independent groups (2, (4) (5) (6) showing 214 specificity ≥ 99% for all the quantitative assays. In addition, not all commercial quantitative 215 anti-SARS-CoV-2 Ab assays were evaluated limiting the scope of the conclusions. 216 Furthermore, neutralizing Ab were not investigated that could have helped determine whether 217 anti-RBD or anti-spike assays are the most correlated with virus neutralization. However, 218 before investigating this, harmonization of neutralizing Ab titers is also necessary to 219 determine a common threshold from which vaccine protection could be predicted, allowing 220 then to find the corresponding threshold with high throughput binding Ab assays. A study 221 comparing different cell-based assays (with either live or pseudotyped viruses) to measure 222 neutralization in vitro is rather reassuring, although differences were found according to the 223 viruses used for pseudotyping (15). However, comparison of cell-based assays with surrogate 224 virus neutralization tests (sVNT) that are based on ELISA, and measuring the competition of 225 Ab and RBD for the binding to ACE, the cellular entry receptor of the virus, did not find good 226 agreement; this is inconvenient, as these assays could be promising given that they have 227 potential for large-scale. 228 In conclusion, the evaluated assays correlated well with each other but a difference in titers 229 remained after adjustment to the same International Standard. Thus, the titer harmonization is 230 not yet completely achieved, but it is better between assays detecting the same Ab against the 231 same antigen than between assays with different targets. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.24.21262475 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org /10.1101 /10. /2021 immune assay, ELFA: enzyme-linked fluorescent assay, N: number of samples, RBD: 349 Receptor Binding Domain, CI: confidence interval. 350 351 352 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org /10.1101 /10. /2021 SARS-CoV-2 Serology Testing: Progress and Challenges TrimericS IgG Assay for the Detection of Circulating Antibodies Anti-SARS-CoV-2 Antibody Levels 259 Measured by the Advise Dx SARS-CoV-2 Assay Are Concordant with Previously 260 Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity. 261 2021 Performance of 263 the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New 264 Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative 278 IgG and IgM Assays among Infected Recovered and Vaccinated Groups. 2021 Anti-Spike Protein Assays to 282 Determine SARS-CoV-2 Antibody Levels: A Head-to-Head Comparison of Five 283 Neutralizing Antibodies Correlate with 287 Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a 288 High Attack Rate. 2020 Correlates of Protection against SARS-CoV-2 in Rhesus 304 CoV-2 Neutralizing Antibodies and Protection from Disease in a Small Animal Model COVID-19: Clinical Sensitivity Specificity and Association with Virus Neutralization 325 WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin Evaluation of Cell-Based and 335 CoV-2 Neutralization Assays. 2021